Skip to main content

Table 6 univariate and multivariate analysis of progression free survival (PFS)

From: Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

 PFSP-value
 at
12 months (%)
at
24 months (%)
univariate
Analysis
multivariate
Analysis
Age
  ≤ 65 years5019  
  > 65 years67200.925 
Gender
 Female8020  
 Male54190.868 
Karnofsky performance status
  > 80%6525  
  ≤ 80%4690.134 
UICC stage
 III5418  
 IV100330.458 
T category
 1–2670  
 3–456200.292 
N category
 0–1330  
 2–361200.235 
Histology
 Squamous cell carcinoma5619  
 Non- Squamous cell carcinoma60200.855 
Tobacco consumption (PY)
 06325  
 20–403813  
  > 4067200.633 
Grading
 Moderately differentiated5050  
 Poorly differentiated5915  
anaplastic50500.831 
PD-L1 expression
 0%8629  
  ≥ 1%31130.0060.061
 CD8+ TILs density    
  ≤ 40%7030  
  > 40%50170.201 
TIME type
 I10060  
 II3020  
 III7114  
 IV4000.0350.144